Following all these results, T-Dxd was granted accelerated approval in August 2022 by the FDA for adult patients with previously treated, unresectable, or metastatic NSCLC, whose tumors have an activating HER2 mutation. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.